

**Priority question for written answer P-000521/2021  
to the Commission**

Rule 138

**Valter Flego** (Renew)

Subject: Vaccine delays

AstraZeneca informed the Commission last week that it would reduce vaccine deliveries in the first quarter by 60% to 31 million doses, rather than the agreed 80 million doses. The President of the Commission, who was expecting the timely delivery of the agreed quantities of vaccines, has responded to this news.

In addition, the EU has ordered as many as 600 million doses of the Pfizer-BioNTech vaccine, which it has already approved and with which it has already started vaccinating citizens. That company last week announced a delay in deliveries over the next few weeks due to work to increase capacity at their Belgian plant.

What was lacking in the procurement procedure was much-needed transparency.

Following such delays, it is obvious that the public vaccination plan will have to be adapted to the new situation.

Has the Commission found a solution yet, and how has it adapted the vaccination programme and timing strategy to this situation?

How many Europeans will be vaccinated by 1 June and how many by 30 September?

Following requests from Parliament to make the contracts publicly available, and following the Commission's announcement that it will facilitate this, when can we expect the documents to be available for inspection?